By phosphorylating AMPK and other substrates, LKB1 is regarded as a major tumour suppressor and regulator of metabolism that acts mainly by inhibiting the mammalian target-of-rapamycin (mTOR) pathway12–14. Here, PRKAA2 is linked to neoplasm.